Pharmacology of CAR T-cell Therapy

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorSarkar, Akash
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentHalasi , Barbara Dóra
dc.contributor.opponentHalasi , Dóra Barbara
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.date.accessioned2025-10-31T07:49:24Z
dc.date.available2025-10-31T07:49:24Z
dc.date.created2025-10-03
dc.description.abstractChimeric Antigen Receptor T-cell (CAR T-cell) therapy has proven to be a major advancement in the field of cancer immunotherapy, providing promising clinical outcomes in the treatment of certain hematological malignancies, where standard treatment modalities such as chemotherapy and hematopoietic stem cell transplantation (HSCT) often fall short. In CAR T-cell therapy, a patient’s own T-cells are collected and isolated and genetically engineering them recognize antigens on tumor cells such as CD19 or BCMA, bypassing the need to bind to the major histocompatibility complex (MHCI) which normally presents antigens to CD8+ cytotoxic T-cells (CTLs). This allows for the direct activation of the CAR T-cells and subsequent tumor cell lysis. Clinical trials and studies have shown high remission and survival rates even in case of relapsed or refractory B-cell malignancies. Despite their success, they face challenges such as the development of toxicity syndromes such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as manufacturing complexity, high costs and limited accessibility. To tackle some of these limitations, research is ongoing and includes the development of newer generation of CARs to expand its indications, allogeneic CARs from donors, as well as combining it with standard therapies and other drugs to improve its efficacy.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent48
dc.identifier.urihttps://hdl.handle.net/2437/398318
dc.language.isoen
dc.rights.infoHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectCAR T-cell
dc.subjectImmunotherapy
dc.subjectLeukemia
dc.subjectLymphoma
dc.subject.dspaceMedicine::Pharmacology
dc.subject.dspaceMedicine
dc.titlePharmacology of CAR T-cell Therapy
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
Pharmacology of CAR T-Cell Therapy_AkashSarkarXSP7G7.pdf
Méret:
3.28 MB
Formátum:
Adobe Portable Document Format
Leírás:
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Medicine)